Nutriband Inc. (NTRB) Stock Analysis & Investment Frameworks
Nutriband Inc. (NTRB) stock analysis on Invetso. Review Nutriband Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nutriband Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Nutriband Inc. Key Financial Metrics
- Market Cap: $70.62M
- Revenue: $2.04M
- ROE: -109.02%
- ROIC: -126.99%
- Dividend Yield: N/A
About Nutriband Inc.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Nutriband Inc. Investment Frameworks
Invetso analyzes Nutriband Inc. (NTRB) across the following frameworks:
- Nutriband Inc. 10Y Growth Potential
- Nutriband Inc. Scenario Analysis
- Nutriband Inc. Risks & Opportunities
- Nutriband Inc. Economic Moat
- Nutriband Inc. Business Model
- Nutriband Inc. Management
- Nutriband Inc. SWOT Analysis
- Nutriband Inc. Porter's 5 Forces
- Nutriband Inc. PESTLE Analysis
- Nutriband Inc. ESG Analysis